Susquehanna Fundamental Investments LLC Invests $912,000 in BioCryst Pharmaceuticals, Inc. $BCRX

Posted by Brenda Bartman on Sep 2nd, 2026

Susquehanna Fundamental Investments LLC purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 91,228 shares of the biotechnology company’s stock, valued at approximately $912,000.

Several other large investors have also recently bought and sold shares of BCRX. BlackRock Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $238,930,000. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. RA Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. grew its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after buying an additional 7,477,000 shares in the last quarter. Finally, State Street Corp increased its position in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after buying an additional 1,265,773 shares during the period. 85.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BCRX has been the subject of a number of recent research reports. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC lowered their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. Finally, Citizens Jmp increased their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

Read Our Latest Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Up 2.3%

NASDAQ:BCRX opened at $9.92 on Wednesday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The stock’s 50-day simple moving average is $9.74 and its 200 day simple moving average is $9.11. The firm has a market capitalization of $2.53 billion, a PE ratio of -6.61 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business’s quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.